News

An approach that removes specific antibodies from a person’s blood is better than a standard, more general blood-cleaning procedure called plasma exchange at clearing the self-reactive antibodies that drive ANCA-associated vasculitis (AAV). That’s according to a small study in China that looked at data from AAV patients with severe…

People with ANCA-associated vasculitis (AAV) often face a high medication burden — managing multiple medications, also known as polypharmacy — with most patients covered by Medicare on five or more treatments at the same time in the first year after their diagnosis, a study found. Among the factors…

Blood levels of globulins — a group of proteins that includes antibodies — when ANCA-associated vasculitis (AAV) is diagnosed can help in forecasting the risk of a patient dying of any cause, a large data study from Korea suggests. “The present study is the first to demonstrate that [total…

Rates of preterm delivery, lower-than-normal birth weight, and maternal disease flares are higher among pregnant women with ANCA-associated vasculitis (AAV) than in the general population, according to a review study. Despite this, “most pregnancies resulted in healthy newborns and manageable, non-life-threatening flares of AAV,” the researchers wrote, suggesting that “pregnancy…

Treatment with Tavneos (avacopan) results in significant and clinically meaningful improvements in health-related quality of life (HRQoL) for people with ANCA-associated vasculitis (AAV), according to findings from the Phase 3 ADVOCATE clinical trial. “The ADVOCATE study is, to our knowledge, the first trial in patients with ANCA-associated vasculitis…

Dosing has begun in a Phase 2 clinical trial of imlifidase, an  antibody-cleaving therapy, in people with ANCA-associated vasculitis (AAV) who have or are at risk of disease-associated acute respiratory distress syndrome (ARDS), Hansa Biopharma, the therapy’s developer, announced. ARDS, a severe complication of AAV, occurs…

Intravenous immunoglobulin (IVIG) therapy appears to be an effective and relatively safe option for people with ANCA-associated vasculitis (AAV), according to real-life study of its use in Spain. All of its 28 AAV patients were resistant to conventional treatments and/or had — or were suspected of having — an…

Developing pulmonary hypertension (PH), which occurs when pressure in the blood vessels that supply the lungs becomes too high, more than triples the mortality risk among people with ANCA-associated vasculitis (AAV), a study finds. PH may be relatively more common in AAV patients than understood, occurring in about…

Blood levels of superoxide dismutase (SOD), an antioxidant enzyme, are significantly lower in people with ANCA-associated vasculitis (AAV) than those without this disease, and poorer outcomes are found in patients with greater reductions, a study reported. Specifically, lower blood SOD levels significantly associated with more inflammation, a greater likelihood…

Nearly three-quarters of ANCA-associated vasculitis (AAV) patients treated with rituximab fail to mount an effective immune response against SARS-CoV-2, the virus that causes COVID-19, following two doses of vaccines. That’s according to data from the U.K.-based OCTAVE trial, which evaluated immune responses to vaccines in patients with reduced immune…